Funding
No sources of funding were used to assist in the preparation of this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Hans Fuchs has received an educational grant from Intuitive Surgical (ESOMAP trial); is a member of the Advisory Board for Activ Surgical, Medtronic, Stryker, and Distal Motion; and holds stock options in Fortimedix Surgical. Florian Gebauer, Patrick S. Plum, Alexander Damanakis, Seung-Hun Chon, Felix Popp, Thomas Zander, Alexander Quaas, Thomas Schmidt, Wolfgang Schröder, and Christiane J. Bruns have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gebauer, F., Plum, P.S., Damanakis, A. et al. ASO Visual Abstract: Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction. Ann Surg Oncol 30, 7513–7514 (2023). https://doi.org/10.1245/s10434-023-13822-8
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-13822-8